"When fully implemented (the DAVA project), the export of fake or spurious drug from the country will not be possible and in case it happens it would be easily traceable," it said in a statement.
The project has won the 2015 eASIA Award under Trade Facilitation category as announced by Asia Pacific Council for Trade Facilitation and Electronic Business (AFACT) in Tehran, it said.
"This project will contribute considerably in enhancing the brand image of our pharmaceutical exporters," it said.
"It is in the pilot stage and will be subsequently made mandatory for all pharmaceutical exports from India," it said.
The DAVA project also aims to cover all the drugs manufactured in India. Indian Pharmaceutical industry has about 250 large units and more than 8,000 small and medium scale units.
The project will provide simpler means to the consumer and regulatory agencies for establishing drug authentication and protect the India's brand image in international trade, the statement said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
